Literature DB >> 11734600

Determining cause of death in prostate cancer: are death certificates valid?

D F Penson1, P C Albertsen, P S Nelson, M Barry, J L Stanford.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11734600     DOI： 10.1093/jnci/93.23.1822

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  39 in total

1.  Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut.

Authors:  Grace Lu-Yao; Peter C Albertsen; Janet L Stanford; Therese A Stukel; Elizabeth S Walker-Corkery; Michael J Barry
Journal:  BMJ       Date:  2002-10-05

2.  Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease.

Authors:  Jennifer L Lund; Linda C Harlan; K Robin Yabroff; Joan L Warren
Journal:  Cancer Invest       Date:  2010-08       Impact factor: 2.176

3.  Cause of death in older men after the diagnosis of prostate cancer.

Authors:  Melanie Ketchandji; Yong-Fang Kuo; Vahakn B Shahinian; James S Goodwin
Journal:  J Am Geriatr Soc       Date:  2008-11-18       Impact factor: 5.562

4.  Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

Authors:  Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Siu-Long Yao
Journal:  JAMA Intern Med       Date:  2014-09       Impact factor: 21.873

5.  Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study.

Authors:  Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson
Journal:  Urology       Date:  2014-09-26       Impact factor: 2.649

6.  Adapting the Elixhauser comorbidity index for cancer patients.

Authors:  Hemalkumar B Mehta; Sneha D Sura; Deepak Adhikari; Clark R Andersen; Stephen B Williams; Anthony J Senagore; Yong-Fang Kuo; James S Goodwin
Journal:  Cancer       Date:  2018-02-01       Impact factor: 6.860

7.  Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.

Authors:  Reith R Sarkar; J Kellog Parsons; Alex K Bryant; Stephen T Ryan; Andrew K Kader; Rana R McKay; Anthony V D'Amico; Paul L Nguyen; Benjamin J Hulley; John P Einck; Arno J Mundt; Christopher J Kane; James D Murphy; Brent S Rose
Journal:  JAMA Intern Med       Date:  2019-06-01       Impact factor: 21.873

8.  Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Karynsa Cetin; Jennifer L Beebe-Dimmer; Jon P Fryzek; Richard Markus; Michael A Carducci
Journal:  Urology       Date:  2009-12-06       Impact factor: 2.649

9.  Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

Authors:  Brent K Hollenbeck; Zaojun Ye; Rodney L Dunn; James E Montie; John D Birkmeyer
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

10.  Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project.

Authors:  V Paul Doria-Rose; Pamela M Marcus
Journal:  Lung Cancer       Date:  2008-06-30       Impact factor: 5.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.